Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 246

1.

Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.

Lim-Abrahan MA, Yu-Gan S, Jain AB, Sobrepena LM, Racho VA.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S35-40. doi: 10.1016/S0168-8227(13)70008-1.

PMID:
23647717
2.

Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Indonesian cohort of the A₁chieve study.

Soewondo P, Lindarto D, Wibisono S, Renaldi O, Dalem-Pemayun TG.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S41-6. doi: 10.1016/S0168-8227(13)70009-3.

PMID:
23647718
3.

Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.

Hussein Z, Lim-Abrahan MA, Jain AB, Goh SY, Soewondo P.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S24-9. doi: 10.1016/S0168-8227(13)70006-8.

PMID:
23647714
4.

Safety and effectiveness of biphasic insulin aspart 30 in a Bangladeshi subgroup of type 2 diabetic patients switched from biphasic human insulin 30: a sub-analysis of the A₁chieve study.

Latif ZA, Pathan MF, Siddiqui MN, Sobhan MJ, Rahman MM, Ashrafuzzaman SM.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S30-4. doi: 10.1016/S0168-8227(13)70007-X.

PMID:
23647716
5.

Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.

Lim-Abrahan MA, Jain AB, Bebakar WM, Seah D, Soewondo P.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S3-9. doi: 10.1016/S0168-8227(13)70003-2.

PMID:
23647715
6.

Clinical experience with BIAsp 30: results from the Indonesian cohort of the international A₁chieve study.

Soewondo P, Pramono RB, Langi YA, Soetedjo NN, Kshanti IA.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S54-9. doi: 10.1016/S0168-8227(13)70011-1.

PMID:
23647720
7.

Safety and effectiveness of insulin aspart in type 2 diabetic patients: results from the ASEAN cohort of the A₁chieve study.

Bebakar WM, Lim-Abrahan MA, Jain AB, Seah D, Soewondo P.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S17-23. doi: 10.1016/S0168-8227(13)70005-6.

PMID:
23647713
8.

Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: results from the A₁chieve study.

El Naggar NK, Soewondo P, Khamseh ME, Chen JW, Haddad J.

Diabetes Res Clin Pract. 2012 Dec;98(3):408-13. doi: 10.1016/j.diabres.2012.09.043.

PMID:
23217267
9.

Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.

Valensi P, Shaban J, Benroubi M, Kawamori R, Borzì V, Shah S, Wenying Y, Prusty V, Hansen JB, Gumprecht J; IMPROVE Study Expert Panel.

Curr Med Res Opin. 2013 Jun;29(6):601-9. doi: 10.1185/03007995.2013.786692. Epub 2013 Apr 12.

PMID:
23488447
10.

Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.

Kaneko S, Chow F, Choi DS, Taneda S, Hirao K, Park Y, Andersen TH, Gall MA, Christiansen JS; BOOST: Intensify All Trial Investigators.

Diabetes Res Clin Pract. 2015 Jan;107(1):139-47. doi: 10.1016/j.diabres.2014.09.026. Epub 2014 Oct 14.

11.

Initiating or switching to biphasic insulin aspart 30 in type 2 diabetes patients from Algeria: a sub-analysis of the A₁chieve study.

Lezzar A, Ayad F, Dahaoui A, Salah-Mansour A, Berrouiguet AY.

Diabetes Res Clin Pract. 2013 Aug;101 Suppl 1:S37-44. doi: 10.1016/S0168-8227(13)70017-2.

PMID:
23958570
12.

Exploring insulin analogue safety and effectiveness in a Maghrebian cohort with type 2 diabetes: results from the A₁chieve study.

Belhadj M, Dahaoui A, Jamoussi H, Farouqi A.

Diabetes Res Clin Pract. 2013 Aug;101 Suppl 1:S4-14. doi: 10.1016/S0168-8227(13)70014-7.

PMID:
23958571
13.

Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.

Dieuzeide G, Chuang LM, Almaghamsi A, Zilov A, Chen JW, Lavalle-González FJ.

Prim Care Diabetes. 2014 Jul;8(2):111-7. doi: 10.1016/j.pcd.2013.07.005. Epub 2013 Aug 14.

PMID:
23953707
14.

Safety and effectiveness of insulin detemir in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.

Soewondo P, Mohamed M, Jain AB, Sy RA, Khoo CM.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S10-6. doi: 10.1016/S0168-8227(13)70004-4.

PMID:
23647712
15.

Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.

Mäkelä JK, Schmüser C, Askonen K, Saukkonen T.

Diabetes Res Clin Pract. 2012 Jan;95(1):10-8. doi: 10.1016/j.diabres.2011.06.006. Epub 2011 Nov 9.

PMID:
22078072
16.

Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial).

Trippe BS, Shepherd MD, Coulter FC, Bhargava A, Brett J, Chu PL, Oyer DS.

Curr Med Res Opin. 2012 Jul;28(7):1203-11. doi: 10.1185/03007995.2012.686444. Epub 2012 Jun 25.

PMID:
22509859
17.

Safety and effectiveness of insulin analogues in Moroccan patients with type 2 diabetes: a sub-analysis of the A₁chieve study.

Chraibi A, Ajdi F, Belkhadir J, El Ansari N, Marouan F, Farouqi A.

Diabetes Res Clin Pract. 2013 Aug;101 Suppl 1:S27-36. doi: 10.1016/S0168-8227(13)70016-0.

PMID:
23958569
18.

Biphasic insulin aspart 30 improved glycemic control in Chinese patients with type 2 diabetes poorly controlled on oral glucose-lowering drugs: a subgroup analysis of the A₁chieve study.

Chen L, Xing X, Lei M, Liu J, Shi Y, Li P, Qin G, Li C, Li Y, Wang Q, Gao T, Hu L, Wang Y, Yang W.

Chin Med J (Engl). 2014;127(2):208-12.

PMID:
24438605
19.

Safety and efficacy of biphasic insulin aspart 30 in type 2 diabetes patients switched from either biphasic or basal human insulin: results from the Gulf cohort of the A1 chieve study.

Almansari A, Khader S, Kharawagh A, AbdelFattah W, Badawy T.

Int J Clin Pract. 2014 Jul;68(7):850-6. doi: 10.1111/ijcp.12391. Epub 2014 Feb 18.

PMID:
24548757
20.

Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.

Franek E, Haluzík M, Canecki Varžić S, Sargin M, Macura S, Zacho J, Christiansen JS.

Diabet Med. 2016 Apr;33(4):497-505. doi: 10.1111/dme.12982. Epub 2015 Nov 17.

Supplemental Content

Support Center